(Reuters) – GlaxoSmithKline mentioned on Monday it had utilized for U.S. approval for its experimental a number of myeloma drug that confirmed significant response in almost a 3rd of sufferers, establishing a battle towards Johnson & Johnson and Genmab’s Darzalex.
FILE PHOTO: A GlaxoSmithKline (GSK) brand is seen on the GSK analysis centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls
New knowledge from the therapy, belantamab mafodotin, confirmed 30 of 97 sufferers skilled a discount of their myeloma cells on the finish of a mid-stage research, DREAMM-2.
The trial was testing belantamab mafodotin, also called GSK2857916, in sufferers who…